Projects

The aim of the Head and Neck Group within the Leipzig Research Center for Civilization Diseases (LIFE) is to facilitate improvements in the treatment and care of head and neck cancer patients through insights from molecular studies.

The Head and Neck Group within the Leipzig Research Center for Civilization Diseases (LIFE) investigates the molecular mechanisms and the diagnostic and prognostic factors of head and neck cancer. For this purpose, we collected phenotypic information from about 300 ...

During 2004 and 2012 the german cancer aid supported the german glioma network (GGN). The GGN is a consortium where university hospitals with clinical focus in neuro-oncology, reference centers for neuroradiology, neuropathology, molecular diagnostics and biometry cooperate. Thanks to the long-term support it was possible to build a network of competence centers for the treatment of brain tumors in Germany wich is characterized by a interdisciplinary collaboration of all specialist disciplines ...

The LIFE-Heart study recruited 7,000 patients with suspected coronary heart disease, manifest heart disease or myocardial infarction. All patients received coronary angiography so that the vascular status in the heart is precisely known. In principle, this examination is not feasible in population-related studies. In addition, the patients were thoroughly examined with regard to the general vascular status and the health of the cardiovascular system. Extensive environmental factors were recorded. ...

Goal of the Leipzig Research Center for Civilization Diseases (LIFE) is the investigation of civilization diseases like depression, diabetes, allergies or cardiovascular diseases. For this purpose we collect as much data as possible regarding health and living conditions of the population in Leipzig and provide these data for scientists of the University of Leipzig and other research institutions.

During 2003 and 2011 the german cancer aid funded the molecular mechanisms in malignant lymphomas (MMML) project. It is based on strongly interacting networks of reference pathologists, lymphoma scientists, bioinformaticians and clinical trial groups. Within the project about 1000 lymphoma samples and controls were characterized by gene expression and copy number arrays. The datasets were supplemented by extensive histopathological and clinical descriptions of the lymphoma cases. The aim of the ...

MMML-MYC-SYS is a interdisciplinary consortium where partners from clinical haemaoncological study groups, pathologists, geneticicts, cell biologists as well as mathematicians, statisticians and bioinformaticists have allied. The goal is to investigate the process of development of B-cell lymphoma under special consideration of mutation of MYC. MYC is known to support the development and growth of tumors. This consortium collected and evaluated comprehensive molecular-genetic data for this purpose. ...

B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study ...